Yale Cancer Center Researchers Show Adding Radiation After Immunotherapy Improves Survival Time for Patients with Advanced Lung Cancer
The results of a phase II clinical trial by Yale Cancer Center (YCC) researchers show adding high-dose radiation after immunotherapy stops working increases survival time for patients with metastatic non-small-cell lung cancer (NSCLC).
Genome screen uncovers new targets for cancer immunotherapy
A new genome-wide screen of 20,000 human genes in T cells have turned up several new candidates to unleash the immune system’s ability to attack a variety of tumor types, Yale Cancer Center researchers report Aug. 22 in the journal Cell.
Yale Cancer Center Partners in Fight to Help Eliminate HPV-related Cancers
Yale Cancer Center joins the Association of American Cancer Institutes (AACI) and its partner organizations to endorse a Call to Action for our nation to work together toward the elimination of human papillomavirus (HPV)-related cancers.
Yale Cancer Center scientists discover molecular key to how cancer spreads
Yale Cancer Center researchers have discovered how metastasis, the spread of cancer cells throughout the body, is triggered on the molecular level, and have developed a tool with the potential to detect those triggers in patients with certain cancers. The discovery could lead to new ways for treating cancer.
Alessandro Santin Recognized as 2019 ASCO Leader in Cancer Care
Research by Alessandro Santin, M.D., professor of gynecology, obstetrics & reproductive sciences and leader of the Disease Aligned Research Team of the Gynecologic Oncology Program at Smilow Cancer Hospital and Yale Cancer Center, has had his research selected as one of the top five advances of the year by the American Society of Clinical Oncology (ASCO).
Early cancer drug data give Amgen hope it has 'cracked KRAS code'
CHICAGO — Decades of research have failed to uncover a therapeutic answer to one of the most well-known genetic drivers of cancer. Yet Amgen thinks it's broken through with an early-stage drug that, in initial results presented Monday at the American Society of Clinical Oncology's annual meeting, spurred tumors to shrink in five of 10 lung cancer patients.
Yale Cancer Center and Smilow Cancer Hospital physicians recognized as CT Magazine 'Best Doctors'
Connecticut Magazine has named 72 Yale Cancer Center and Smilow Cancer Hospital physicians to its 2019 Best Doctors guide. Published in the magazine’s June issue, the Best Doctors list consists of 782 Connecticut physicians from 78 medical specialties.
Yale Study Finds Link Between Medicaid Expansion and Equity in Cancer Care
Racial disparities in timely cancer treatment disappeared in states that expanded Medicaid under the Affordable Care Act (ACA), according to an analysis of over 30,000 health records led by researchers at Yale Cancer Center. The findings were presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting.
Lung Cancer Research Foundation Announces New Scientific Advisory Board Chair
NEW YORK, May 23, 2019 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) today announced that Dr. Katerina Politi has been named the chair of its Scientific Advisory Board. Politi, an Associate Professor of Pathology and Internal Medicine (in the Section of Medical Oncology) at Yale School of Medicine, will be taking over the role from Dr. James B. Dougherty, who has held the chair position for 14 years.
A Successful Form of Immunotherapy For Blood Cancers Shows Promise For Other Types of the Disease
An innovative new immunotherapy treatment at the Yale Cancer Center and Smilow Cancer Hospital called CAR T-cell therapy has shown remarkable success in treating certain blood cancers, including some for which all other treatment options have failed.
Yale Study Identifies How Cancer Drug Inhibits DNA Repair in Cancer Cells
Yale Cancer Center researchers have found that a cancer drug thought to be of limited use possesses an unforeseen property. It is able to stop certain cancer cells from repairing their DNA in order to survive. The study suggests that combining this drug, cediranib, with other agents could potentially deliver a lethal blow in cancer that uses a specific process to create DNA repair cells.